Chicago, Sept. 29 – SciVision Biotech Inc. raised NT$400 million from its offering of zero-coupon three-year convertible corporate bonds, according to an announcement.
The company announced the domestic offering in May.
According to an earlier notice, the bonds have a face value per bond of NT$100,000 and were to be issued at par.
President Securities Corp. was the underwriter or agent.
Horizon Securities Co., Ltd. is the principal paying agent.
Proceeds will be used to repay bank loans and increase working capital.
Based in Kaohsiung, Taiwan, SciVision is a manufacturer of medical-grade hyaluronic acid products.
| Issuer: | SciVision Biotech Inc.
|
| Amount: | NT$400 million
|
| Issue: | Convertible corporate bonds
|
| Tenor: | Three years
|
| Bookrunner: | President Securities Corp.
|
| Trustee: | Cathay United Bank Co. Ltd.
|
| Coupon: | 0%
|
| Price: | Par
|
| Yield: | 0%
|
| Announcement date: | Sept. 29
|
| Distribution: | Taiwan
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
